Filing Flows › Xeris Biopharma Holdings (XERS) › Royalty, contract and other revenue revenue
Xeris Biopharma Holdings (XERS) Royalty, contract and other revenue revenue by quarter
Xeris Biopharma Holdings' Royalty, contract and other revenue revenue was $958K in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 7 quarters it ranged from $317K (Q3 2025) to $3.8M (Q2 2025).
| Quarter | Royalty, contract and other revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $958K | -13% | +202% |
| Q2 2026 | $1.1M | +63% | -71% |
| Q1 2026 | $673K | -72% | -71% |
| Q4 2025 | $2.4M | +650% | — |
| Q3 2025 | $317K | -92% | — |
| Q2 2025 | $3.8M | +65% | — |
| Q1 2025 | $2.3M | — | — |
Q3 2026 at a glance
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xeris Biopharma Holdings' Royalty, contract and other revenue revenue?
Xeris Biopharma Holdings' Royalty, contract and other revenue revenue was $958K in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has Xeris Biopharma Holdings' Royalty, contract and other revenue revenue changed?
Over the last 7 quarters it ranged from $317K (Q3 2025) to $3.8M (Q2 2025).
Q3 2026 results → · How Xeris Biopharma Holdings makes money →